12th ANNUAL CALIFORNIA CANCER CONSORTIUM CONFERENCE

“Recent Advances and New Directions in Cancer Therapy”

August 12-14, 2016
The Westin Pasadena
Pasadena, CA

Presented by the California Cancer Consortium

University of California Davis Comprehensive Cancer Center
Sacramento, CA

City of Hope Comprehensive Cancer Center
Duarte, CA

University of Southern California/Norris Comprehensive Cancer Center
Los Angeles, CA

Stanford Cancer Institute
Stanford, CA

Conference Chairs:
Primo Lara, Jr., M.D. | Edward Newman, Ph.D.
Robert Morgan, M.D.

Educational Steering Committee:
David Gandara, M.D.
Shivaani Kummar, M.D.
Heinz-Josef Lenz, M.D.

Sponsored by:
THE MEDICAL EDUCATOR CONSORTIUM
PROGRAM CHAIRS

Primo Lara, Jr., M.D.
Professor of Medicine
University of California Davis School of Medicine
Associate Director for Translational Research
University of California Davis Comprehensive Cancer Center

Edward Newman, Ph.D.
Associate Professor, Cancer Biology
Co-Leader of the Development Cancer Therapeutics Program
Core Facility
City of Hope Comprehensive Cancer Center Duarte, CA

Robert Morgan, M.D.
Professor of Medicine
Co-director, Gynecological Cancers Program
City of Hope Comprehensive Cancer Center Duarte, CA

STEWING COMMITTEE

David R. Gandara, M.D.
Professor of Medicine
University of California Davis School of Medicine
Senior Advisor to the Director, University of California Davis Comprehensive Cancer Center

Shivaani Kummar, M.D.
Professor of Medicine
Stanford University School of Medicine

Heinz-Josef Lenz, M.D.
Professor of Medicine and Preventive Medicine, Section Head of GI Oncology
University of Southern California, Keck School of Medicine
Associate Director for Clinical Research, University of Southern California Norris Comprehensive Cancer Center

DISTINGUISHED FACULTY

Mehrdad Abedi, M.D.
Professor of Medicine
University of California Davis School of Medicine

Christine Brown, Ph.D.
Associate Research Professor
City of Hope Comprehensive Cancer Center

Helen Chew, M.D.
Professor of Medicine
University of California Davis School of Medicine

Warren Chow, M.D.
Clinical Professor
City of Hope Comprehensive Cancer Center

Vincent Chung, M.D.
Assistant Professor, Department of Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center

A. Dimitrios Colevas, M.D.
Associate Professor of Medicine
Stanford University School of Medicine

Mihaela Cristea, M.D.
Associate Clinical Professor, Department of Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center

Tanya Dorff, M.D.
Assistant Professor
University of Southern California Keck School of Medicine
Norris Comprehensive Cancer Center

Oliver Dorigo, M.D., Ph.D.
Professor
Stanford University School of Medicine

Anthony El-Khoueiry, M.D.
Associate Professor
University of Southern California Keck School of Medicine
Norris Comprehensive Cancer Center

Paul Frankel, Ph.D.
Staff Scientist, Division of Biostatistics, Department of Information Sciences
Beckman Research Institute, City of Hope Comprehensive Cancer Center

David R. Gandara, M.D.
Professor of Medicine, University of California Davis School of Medicine
Senior Advisor to the Director, University of California Davis Comprehensive Cancer Center

Barbara Gitlitz, M.D.
Associate Professor of Medicine, Keck School of Medicine
University of Southern California, Norris Comprehensive Cancer Center

Susan Groshen, Ph.D.
Professor of Medicine and Director, Biostatistics Core
University of Southern California, Norris Comprehensive Cancer Center

Alex Herrera, M.D.
Assistant Professor, Department of Hematology and Hematopoietic Cell Transplantation
City of Hope Comprehensive Cancer Center

James Hu, M.D.
Assistant Professor of Medicine, Keck School of Medicine
University of Southern California, Norris Comprehensive Cancer Center

Brian Jonas, M.D., Ph.D.
Assistant Professor, Division of Hematology/Oncology, University of California Davis School of Medicine

Kevin Kelly, M.D., Ph.D.
Associate Professor
University of Southern California, Keck School of Medicine

Marianna Koczywas, M.D.
Clinical Professor of Medicine
City of Hope Comprehensive Cancer Center

Shivaani Kummar, M.D.
Professor of Medicine
Stanford University School of Medicine

Heinz-Josef Lenz, M.D.
Professor of Medicine and Preventive Medicine, Section Head of GI Oncology
University of Southern California, Keck School of Medicine
Associate Director for Clinical Research, University of Southern California Norris Comprehensive Cancer Center
COURSE DESCRIPTION
This conference aims to provide up-to-date information to the clinician regarding new advances in cancer biology, diagnosis, and treatment. It will bring together respected opinion leaders, practicing clinicians and scientists engaged in clinical cancer research to discuss the latest cancer diagnostic and therapeutic advances. Topics focus on the major cancers and drug development areas, including signal transduction/CDK inhibition, angiogenesis inhibition, PI3K/mTOR inhibition, antibody-drug conjugates, and immunotherapy, among others. This annual conference also includes interactive roundtable discussion forums with participation of cancer care experts from the California Cancer Consortium, and features renowned professionals from academia, patient advocacy, government, payer, industry, and business realms of cancer care.

EDUCATIONAL OBJECTIVES
After participating in this educational activity, you should be able to:

• Identify signaling and immunotherapeutic pathways that are involved in the growth and metastases of various tumor types, and identify specific opportunities for therapeutic intervention.

• Describe recent advances in the molecular phenotyping of cancer and relate these to the optimal management of patients with cancer.

• Based on recent clinical trials, assess the efficacy of novel therapeutic strategies in the treatment of patients with cancer.

• Discuss new and emerging clinical trial designs that can test and validate new therapeutic strategies for cancer patients.

TARGET AUDIENCE
This program will be of interest to medical oncologists, hematologists, surgical oncologists, radiation oncologists, diagnostic radiologists, pulmonologists, urologists, gastroenterologists, pathologists, fellow and resident trainees, advanced care practitioners, registered nurses, physician assistants, clinical research coordinators, biostatisticians, and others involved in oncologic drug development and clinical care.

NEEDS ASSESSMENT
This course was developed in cooperation with the academic faculty and scientists belonging to the California Cancer Consortium to provide an annual in-depth exposure and review of new advances in cancer drug development, biology, biomarkers, diagnosis, and therapy. The agenda and format was specifically designed to address knowledge gaps identified from prior course participant evaluations and unsolicited comments from practicing oncologists (from private practice, academia) as well as scientists involved in cancer clinical trials. This area of knowledge will be best addressed by an in-depth conference on systemic therapy of malignancies (both solid and hematologic), with ample time provided for interaction by attendees with expert faculty. It is expected that this course will enhance the clinical competence of clinicians in managing the care of the cancer patient, and subsequently, improve patient outcomes.

ACCREDITATION
The Medical Educator Consortium is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Medical Educator Consortium designates this educational activity for a maximum of 15 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 15.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE
The Medical Educator Consortium (MEC) adheres to the ACCME Standards for Commercial Support. All persons that will be in a position to control the content of the CME Activity are required to disclose all relevant financial Relationships. Faculty disclosure forms outlining this information will be made available to all participants prior to the educational activity. MEC has also implemented a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.

NURSING CONTINUING MEDICAL EDUCATION
Continuing Medical Education is acceptable for meeting RN continuing education requirements, as long as the course is AMA PRA Category 1 Credits™, and has been taken within the appropriate time frames.
12th Annual California Cancer Consortium Conference
“Recent Advances and New Directions in Cancer Therapy”

FRIDAY, AUGUST 12th, 2016

1:30 - 3:00 pm Registration & Visit Exhibits
1:30 - 2:30 pm CCC Business Meeting (by invitation only)
3:00 pm Welcome and Introductions
3:05 pm Pre-session Survey/MOC Pre-Questionnaire

Session 1: Inhibition of Signal Transduction and Angiogenesis Pathways
  Chairs: Primo Lara (UC Davis) and Edward Newman (City of Hope)

  3:15 pm EGFR Inhibitors: State of the Art
  Marianna Koczywas, City of Hope
  3:35 pm Question-and-Answer Session
  3:40 pm MET Pathway Inhibitors
  Ravi Salgia, City of Hope
  4:00 pm Question-and-Answer Session
  4:05 pm FGF and FGFR as Therapeutic Targets
  Philip C. Mack, UC Davis
  4:25 pm Question-and-Answer Session
  4:30 pm Angiogenesis Inhibitors
  Oliver Dorigo, Stanford
  4:50 pm Question-and-Answer Session
  4:55 pm EphB4 Inhibitors
  Barbara Gitlitz, USC
  5:15 pm Question-and-Answer Session
  5:20 pm Refreshment Break & Visit Exhibits

Session 2: Clinical Trial Design
  Chairs: Susan Groshen (USC) and Paul Frankel (City of Hope)

  5:35 pm Phase I Designs: Is the Answer You Get the One You Want?
  Paul Frankel, City of Hope
  5:50 pm Question-and-Answer Session
  5:55 pm How to Select the Right Phase 2 Endpoints
  Susan Groshen, USC
  6:10 pm Question-and-Answer Session
  6:15 pm Phase Ib Trials with Expansion Cohorts and
  Phase 2 Trials: a Case for Seamless Study Design
  Jeff Longmate, City of Hope
  6:30 pm Question-and-Answer Session
  6:35 pm Roundtable Discussion: Statistical Considerations in the ET-CTN era
  Moderator: Edward Newman (City of Hope)
  Participants: Jeff Longmate, Paul Frankel, Susan Groshen, David Gandara
  6:55 pm Post-session Survey
  7:00 - 8:00 pm Wine and Cheese Welcome Reception & Visit Exhibits
CONFERENCE AGENDA

SATURDAY, AUGUST 13th, 2016

7:30 am  Registration, Refreshments & Visit Exhibits
8:00 – 8:45 am  Breakfast & Learn Symposia (non CME)
9:00 am  Introduction
9:05 am  Pre-session Survey

Session 3: Cancer Immunotherapy  
Chairs: Tianhong Li (UC Davis) and Primo Lara (UC Davis)

9:10 am  Immunology for Dummies: A Review  
Kim Margolin, City of Hope
9:30 am  Question-and-Answer Session
9:35 am  Checkpoint inhibitor therapy  
Primo Lara, UC Davis
9:55 am  Question-and-Answer Session
10:00 am  Cell Based Immunotherapy Approaches  
Christine Brown, City of Hope
10:20 am  Question and Answer
10:25 am  Cancer Vaccines  
Vincent Chung, City of Hope
10:45 am  Question-and-Answer Session
10:50 am  Close Morning Session

11:50 – 12:50 pm  Lunch & Learn Symposia (non cme)
12:50 – 1:05 pm  Refreshments & Visit Exhibits

Session 4: Lung Cancer  
Chairs: Marianna Koczywas (City of Hope) and Jonathan Riess (UC Davis)

10:50 am  Non-Small Cell Lung Cancer as a Model for Biomarker Driven and Personalized Therapy  
David Gandara, UC Davis
11:10 am  Question-and-Answer Session
11:15 am  Small Cell Lung Cancer and Thymoma: What’s New?  
Jonathan Riess, UC Davis
11:35 am  Question-and-Answer Session
11:40 am  Close Morning Session
11:50 – 12:50 pm  Lunch & Learn Symposia (non cme)
12:50 – 1:05 pm  Refreshments & Visit Exhibits

Session 5: Gastrointestinal Malignancies  
Chairs: Robert Morgan (City of Hope)

1:05 pm  Systemic Therapy for Colorectal Carcinoma in the Adjuvant and Metastatic Settings  
Heinz-Josef Lenz, USC
1:25 pm  Question-and-Answer Session
1:30 pm  New Developments in Esophagogastric and Pancreatic Cancers  
Anthony El-Khoueiri, USC
1:50 pm  Question-and-Answer Session
**Session 6: Hematologic Malignancies**  
*Chairs: Brian Jonas (UC Davis) and Alex Herrera (City of Hope)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:55 pm</td>
<td>New Developments in Acute Leukemia</td>
<td>Kevin Kelly, USC</td>
</tr>
<tr>
<td>2:15 pm</td>
<td>Question-and-Answer Session</td>
<td></td>
</tr>
<tr>
<td>2:20 pm</td>
<td>Multiple Myeloma: Current and Future Directions</td>
<td><em>Aaron Rosenberg, UC Davis</em></td>
</tr>
<tr>
<td>2:40 pm</td>
<td>Question-and-Answer Session</td>
<td></td>
</tr>
<tr>
<td>2:45 pm</td>
<td>Chronic Lymphocytic Leukemia: Updates</td>
<td><em>Tanya Siddiqi, City of Hope</em></td>
</tr>
<tr>
<td>3:05 pm</td>
<td>Question and Answer Session</td>
<td></td>
</tr>
<tr>
<td>3:10 – 3:25 pm</td>
<td>Refreshment break, Visit Exhibits</td>
<td></td>
</tr>
</tbody>
</table>

**Session 7: Genitourinary Malignancies**  
*Chairs: Primo Lara (UC Davis) and Sarmad Sadeghi (USC)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:25 pm</td>
<td>Castration Resistant Prostate Cancer Therapy</td>
<td><em>Tanya Dorff, USC</em></td>
</tr>
<tr>
<td>3:45 pm</td>
<td>Question-and-Answer Session</td>
<td></td>
</tr>
<tr>
<td>3:50 pm</td>
<td>Updates in Renal Cell Carcinoma Drug Development</td>
<td><em>Sarmad Sadeghi, USC</em></td>
</tr>
<tr>
<td>4:10 pm</td>
<td>Question-and-Answer Session</td>
<td></td>
</tr>
<tr>
<td>4:15 pm</td>
<td>Bladder Cancer: Chemotherapy and Beyond!</td>
<td><em>Sandya Srinivas, Stanford</em></td>
</tr>
<tr>
<td>4:35 pm</td>
<td>Question and Answer Session</td>
<td></td>
</tr>
</tbody>
</table>

**Session 8: Gynecologic Cancer**  
*Chair: Oliver Dorigo, Stanford*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:40 pm</td>
<td>Management of Ovarian Cancer in 2016</td>
<td><em>Robert Morgan, City of Hope</em></td>
</tr>
<tr>
<td>5:00 pm</td>
<td>Question-and-Answer Session</td>
<td></td>
</tr>
<tr>
<td>5:05 pm</td>
<td>New Approaches to Cervix and Endometrial Cancer</td>
<td><em>Mihaela Cristea, City of Hope</em></td>
</tr>
<tr>
<td>5:25 pm</td>
<td>Question-and-Answer Session</td>
<td></td>
</tr>
<tr>
<td>5:30 pm</td>
<td>Post-session Survey</td>
<td></td>
</tr>
</tbody>
</table>
### Conference Agenda

**SUNDAY, AUGUST 14th, 2016**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am</td>
<td>Registration, Refreshments &amp; Visit Exhibits</td>
</tr>
<tr>
<td>7:15 am – 8:15 am</td>
<td>Breakfast &amp; Learn Symposia (non cme)</td>
</tr>
<tr>
<td>8:15 am</td>
<td>Introduction</td>
</tr>
<tr>
<td>8:20 am</td>
<td>Pre-session Survey</td>
</tr>
</tbody>
</table>

**Session 9: Breast Cancer**  
Chair: Tianhong Li (UC Davis)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 8:25 am | Hormone Receptor Positive Breast Cancer: What’s New?  
*Helen Chew, UC Davis* |
| 8:45 am | Question-and-Answer Session                                           |
| 8:50 am | Triple Negative Breast Cancer: Emerging Strategies  
*George Sledge, Stanford* |
| 9:10 am | Question-and-Answer Session                                           |

**Session 10: Rapid Review of Emerging and New Developments in Specific Tumor Types**  
Chairs: Warren Chow (City of Hope) and Przemyslaw Twardowski (City of Hope)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 9:15 am | Malignant Melanoma and other Cutaneous Tumors  
*Emanuel Maverakis, UC Davis* |
| 9:30 am | Question-and-Answer Session                                           |
| 9:35 am | Malignant Lymphomas  
*Joseph Tuscano, UC Davis* |
| 9:50 am | Question-and-Answer Session                                           |
| 9:55 am | Soft Tissue Sarcomas  
*James Hu, USC* |
| 10:10 am | Head and Neck Cancer  
*A. Dimitrios Colevas, Stanford* |
| 10:15 am | Question-and-Answer Session                                           |
| 10:30 am | Refreshment Break & Visit Exhibits                                     |

**Session 11: Rapid Review of Emerging Therapeutic Strategies in Oncology**  
Chairs: Tim Synold (City of Hope) and Edward Newman (City of Hope)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 10:50 am | Targeting DNA Damage Repair (PARP, ATR inhibitors)  
*Shivaani Kummar, Stanford* |
| 11:05 am | Question-and-Answer Session                                           |
| 11:10 am | Targeting Heat Shock Proteins                                         |
| 11:25 am | Question-and-Answer Session                                           |
| 11:30 am | Newer Cytotoxics (e.g., eribulin, nab-paclitaxel)  
*David Quinn, USC* |
| 11:45 am | Question-and-Answer Session                                           |
| 11:50 am | Chronic Myeloid Leukemia: Overcoming Resistance with New Agents  
*Mehrdad Abedi, UC Davis* |
| 12:05 pm | Question-and-Answer Session                                           |
| 12:10 pm | Micro-RNAs in Oncology  
*Guido Marcucci, City of Hope* |
| 12:25 pm | Question-and-Answer Session                                           |
| 12:30 pm | Post-session Survey                                                   |
| 12:35 pm | Closing and Adjourn                                                   |
The Westin Pasadena welcomes guests with a full complement of facilities and amenities, all designed to ensure you leave feeling better than when you arrived. We prioritize convenience and simplicity with our 24-hour Business Center, where you can put tasks behind you with ease, as well as Concierge services, for professional guidance on enjoying the best Pasadena has to offer. For reenergizing and clearing your mind, take advantage of our light-filled WestinWORKOUT® Fitness Studio and our alluring outdoor heated pool, with gorgeous views.

Enjoy some of the finest views of the San Gabriel Mountains and the Pasadena area from The Westin Pasadena, or step out to partake in the colorful spirit of downtown. Shoppers and food-lovers alike will revel in the remarkable range of options surrounding us. Just a few minutes on foot from the hotel, the Paseo Colorado features premier dining and retail outlets plus a cinema. Less than a mile away, historic Old Pasadena’s charming storefronts house 200 shops plus a wide array of restaurants and night spots.

The Westin is located within walking distance of the Pacific Asia Museum areas, while the California Technical Institute, the historic Tournament of Roses house, and the Norton Simon Museum are all less than two miles away. A ten-minute drive will take you to the resplendent Huntington Library, with its extensive art collections and botanical gardens.

Golf enthusiasts will enjoy the 36-hole, William P. Bell-designed Brookside Golf Club, just a five-minute drive away. The nine-hole Eaton Canyon course is 15 minutes away in the San Gabriel foothills, and Santa Anita Park—a famous thoroughbred racetrack—is equally close by. The Rose Bowl, a world-famous sports and entertainment venue boasting beautiful greenery and cliff sides, is only five minutes away by car.

The Westin Pasadena is offering special rates during this conference of $185 single or double room plus tax, European Plan (no meals). The cutoff date to make reservations is July 11th, 2016, after this date reservations are subject to hotel availability.

Make your hotel reservations by calling 1-800.937.8461 and use group code “12th Annual Cancer Consortium”

CONFERENCE MANAGEMENT
MEETING EVENTS & CONFERENCE COORDINATORS, INC (MECC)
6619 South Dixie Highway, #341
Miami, FL 33143
Telephone: 305.663.1628
Fax: 305.675.2718
Website: www.meccinc.com
Email: tvalls@meccinc.com

Register online at www.meccinc.com under upcoming events.
Registration Form

Name ____________________________________________ Degree ________________________

Address __________________________________________________________________________

Telephone (___) ____________________________ Fax (___) _____________________________

Email Address ____________________________

Specialty _________________________________

TYPE OF PRACTICE:  □ Private    □ Academic
□ Hospital   □ Other

REGISTRATION FEE: □ $150  Physician
□ $ 75  Nurse, Nurse Practitioner, Resident, Fellow, Students, Non-physician researchers and staff (e.g., CRAs)
□ $250  Industry Professional
□ $ 50  Optional Fee for Maintenance of Certification Credits

MOC Requirements
ABIM ID# _________ (6 digits)
Date of Birth MM/DD _______________________

Refunds must be provided in writing prior to July 8th, 2016. A $50 administrative charge will be deducted for all refunds prior to July 8th, after July 8th no refunds will be provided.

Enclosed is my check i/a/of $____________ for the registration of this conference.

I authorize MECC to charge my credit card i/a/o $____________ for the registration of this course using the following credit card.

Name as it appears on the card ____________________________ Exp. Date __________

Card number __________________________________________ CVV Code: ________

Authorized signature __________________________________________________________________

For those requiring special assistance, contact MECC at 305.663.1628 or via email tvalls@meccinc.com no later than July 8th, 2016.
12th ANNUAL CALIFORNIA CANCER CONSORTIUM CONFERENCE
“Recent Advances and New Directions in Cancer Therapy”

August 12-14, 2016
The Westin Pasadena, Pasadena, CA